Intralipid Shortage: What Providers and Prescribers Need to Know in 2026

Intralipid (lipid injectable emulsion 20%, Fresenius Kabi) has been the cornerstone of IV lipid delivery in parenteral nutrition for over 50 years. While it is not currently on the FDA's national Drug Shortage Database, providers managing patients on home or hospital PN need to stay ahead of the access challenges that can affect Intralipid availability. This briefing provides an evidence-based overview of the supply landscape, clinical alternatives, and prescribing strategies for 2026.

Current Supply Status (2026)

As of 2026, Intralipid is not listed as a shortage product on the FDA Drug Shortage Database. Fresenius Kabi has maintained production. However, providers should be aware of the following structural supply vulnerabilities:

Single-manufacturer dependency. There is no FDA-approved generic for Intralipid. All branded supply originates from Fresenius Kabi's manufacturing facilities.

IV supply chain fragility. The 2024 Hurricane Helene disruption at Baxter's North Carolina facility — which produced IV fluids across multiple hospitals — demonstrated how a single manufacturing disruption can cascade rapidly. A similar event affecting Fresenius Kabi could impact Intralipid supply nationally.

Home infusion pharmacy variability. Home infusion pharmacies maintain their own buffer stock. Demand surges or shipping disruptions can deplete individual pharmacy supplies even when national supply is adequate.

Clinical Alternatives to Intralipid: Current FDA-Approved Options

When Intralipid is unavailable, providers have several FDA-approved alternatives. The choice depends on the patient's clinical profile, underlying diagnosis, and potential for PNALD:

SMOFlipid 20% (Fresenius Kabi): Multi-oil emulsion (30% SO, 30% MCT, 25% OO, 15% FO). FDA-approved 2016 for adults. Lower omega-6:omega-3 ratio (2.5:1 vs. 7:1 for Intralipid), higher alpha-tocopherol content (200 mg/L vs. 38 mg/L). Preferred for patients at risk of PNALD, inflammatory states, or in critical illness. Used off-label in pediatric patients at many centers.

Clinolipid 20% (Baxter): 80% OO / 20% SO blend. FDA-approved for adults. Rich in oleic acid (omega-9), lower PUFA content. Monitor for EFAD with extended use. Suitable when omega-3 FO content of SMOFlipid is not desired (e.g., patients with increased bleeding risk).

Omegaven 10% (Fresenius Kabi): 100% fish oil. FDA-approved in 2018 for pediatric patients (birth-17y) with PNAC. Not approved for routine adult or preventive use. Reserve for established PNALD in pediatric patients per institution protocol.

Nutrilipid 20%: 100% soybean oil, clinically similar to Intralipid. Direct substitute when available from an alternative distributor.

Prescribing Strategies During Supply Disruptions

When supply constraints require prescribing changes, the following strategies are consistent with current ASPEN guidelines and ASHP shortage guidance:

Write for a lipid class rather than a specific brand. For patients where the specific fatty acid profile is not critical, prescribing 'IV lipid emulsion 20%' allows the compounding pharmacy to dispense whichever brand is in stock.

Consider IV lipid minimization. For stable adult patients where supply is critically short, reducing the lipid component of PN to 1 g/kg/day (from 2-3 g/kg/day) can temporarily stretch supply while meeting EFAD prevention thresholds (8-10% of calories from EFA).

Prioritize patients with highest clinical need. In a shortage situation, prioritize neonates and patients with no enteral access over patients who can receive some oral/enteral nutrition. Work with your institution's pharmacy to create a tiered allocation plan.

Account for propofol lipid load. Propofol is formulated in a 10% soybean oil emulsion. ICU patients on propofol are receiving lipid calories that count toward the daily maximum (3 g fat/kg/24h). Adjust Intralipid dosing accordingly.

Supporting Your Patients With Home PN

For providers managing home PN patients, communication with the home infusion pharmacy is critical during supply disruptions. Consider the following:

Proactively notify your home infusion pharmacy of any formulary flexibility you've authorized (e.g., "SMOFlipid acceptable as substitute for Intralipid")

Ensure your patients have clinical documentation sufficient to enroll with a backup pharmacy if needed

Educate patients to contact you immediately if their pharmacy reports a supply problem — don't wait for the patient to run out

medfinder for Providers offers a streamlined way to check pharmacy stock availability for your patients. Visit medfinder.com/providers to learn how the platform can help your clinical team identify which pharmacies near your patients have Intralipid in stock.

Monitoring and Safety Considerations During Lipid Emulsion Transitions

When transitioning between IV lipid emulsion products, providers should monitor:

Serum triglycerides — baseline and 4 hours after infusion rate change; hold lipids if TG > 1,000 mg/dL

Liver function tests — ALT, AST, total bilirubin, direct bilirubin (especially in pediatric patients)

Essential fatty acid panel — if switching to lower-PUFA emulsions (Clinolipid, Omegaven) long-term

Coagulation parameters — vitamin K content varies between emulsions and may affect INR in patients on warfarin

For a provider-focused guide on helping patients locate Intralipid, see: How to help your patients find Intralipid in stock.